HK1253913A1 - 作為干擾素 γ 抑制劑的三嗪衍生物 - Google Patents

作為干擾素 γ 抑制劑的三嗪衍生物

Info

Publication number
HK1253913A1
HK1253913A1 HK18113061.7A HK18113061A HK1253913A1 HK 1253913 A1 HK1253913 A1 HK 1253913A1 HK 18113061 A HK18113061 A HK 18113061A HK 1253913 A1 HK1253913 A1 HK 1253913A1
Authority
HK
Hong Kong
Prior art keywords
interferon
triazine derivatives
gamma inhibitors
gamma
inhibitors
Prior art date
Application number
HK18113061.7A
Other languages
English (en)
Inventor
Laurence Harbige
Michael Leach
Original Assignee
Univ Greenwich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510356.7A external-priority patent/GB201510356D0/en
Priority claimed from GBGB1604394.5A external-priority patent/GB201604394D0/en
Application filed by Univ Greenwich filed Critical Univ Greenwich
Publication of HK1253913A1 publication Critical patent/HK1253913A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18113061.7A 2015-06-12 2018-10-12 作為干擾素 γ 抑制劑的三嗪衍生物 HK1253913A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510356.7A GB201510356D0 (en) 2015-06-12 2015-06-12 Cyclic triazo and diazo sodium channel blockers
GBGB1604394.5A GB201604394D0 (en) 2016-03-15 2016-03-15 Interferon gamma inhibitors
PCT/GB2016/051711 WO2016198878A1 (en) 2015-06-12 2016-06-10 Triazine derivatives as interferon-gamma inhibitors

Publications (1)

Publication Number Publication Date
HK1253913A1 true HK1253913A1 (zh) 2019-07-05

Family

ID=56131564

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113061.7A HK1253913A1 (zh) 2015-06-12 2018-10-12 作為干擾素 γ 抑制劑的三嗪衍生物

Country Status (8)

Country Link
US (1) US10576086B2 (zh)
EP (1) EP3307273B1 (zh)
JP (2) JP2018524302A (zh)
CN (2) CN115737651A (zh)
CA (1) CA3021424C (zh)
ES (1) ES2858750T3 (zh)
HK (1) HK1253913A1 (zh)
WO (1) WO2016198878A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006080D0 (en) 2020-04-24 2020-06-10 Univ Greenwich Cytokine storm syndrome
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153787C (da) 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
JP2000095737A (ja) * 1998-09-25 2000-04-04 Fuji Photo Film Co Ltd キノンメチド化合物
US20040029934A1 (en) 2000-12-28 2004-02-12 Kiyoshi Ebihara Pharmaceutical emulsion preparation
BR0116658A (pt) 2001-01-04 2003-12-30 Daiichi Seiyaku Co Preparação farmacêutica contendo ciclodextrina
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
AU2007257959A1 (en) * 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
GB0800741D0 (en) * 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB2471729A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471713A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
EP2791168A1 (en) * 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Also Published As

Publication number Publication date
US20180169105A1 (en) 2018-06-21
EP3307273B1 (en) 2020-12-09
CA3021424A1 (en) 2016-12-15
CN107921046A (zh) 2018-04-17
EP3307273A1 (en) 2018-04-18
CN115737651A (zh) 2023-03-07
WO2016198878A1 (en) 2016-12-15
US10576086B2 (en) 2020-03-03
JP7332236B2 (ja) 2023-08-23
CN107921046B (zh) 2022-10-14
ES2858750T3 (es) 2021-09-30
CA3021424C (en) 2023-03-21
JP2018524302A (ja) 2018-08-30
JP2022037243A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HK1255045A1 (zh) 取代的氧代吡啶衍生物
HK1255269A1 (zh) 作為parp抑制劑的雜芳基衍生物
HUE059324T2 (hu) Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
IL255750A (en) Heterocyclic compounds as kinase inhibitors
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1251572A1 (zh) 作為ddr1抑制劑的三氮雜-螺癸酮類化合物
IL258438B (en) 2-Aminoquinoline derivatives as p70s6 kinase inhibitors
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
HK1253913A1 (zh) 作為干擾素 γ 抑制劑的三嗪衍生物
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors